Randomised controlled trial of a tailored SMS intervention (MiQuit) for pregnant smokers in routine antenatal care

Katharine A Foster1,2, Felix Naughton3,2, Sue Cooper1,2, Joanne Emery3,2, Jo Leonardi-Bee4,2, Stephen Sutton5,2, Matthew Jones1,2, Michael Ussher2,2, Rachel Whitmore1,2, Matthew Leighton1, Alan Montgomery1, Steven Parrott1,2, Tim Coleman1,2

1. Division of Primary Care, University of Nottingham, Nottingham, UK 2. UK Centre for Tobacco and Alcohol Studies, University of Nottingham, Nottingham, UK 3. School of Health Sciences, University of East Anglia, Norwich, UK 4. Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK 5. Behavioural Science Group, University of Cambridge, Cambridge, UK 6. Population Health Research Institute, St George’s University of London, London, UK 7. Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK. B. Department of Health Sciences, University of York, York, UK

AIMS
To undertake a randomised controlled trial (RCT) in order to provide estimates of key parameters for a definitive effectiveness trial of the MiQuit intervention.

METHODS
- A multi-centre, parallel group RCT across 16 NHS Acute Trusts. NHIR CRN research staff recruited in antenatal clinics.
- Pregnant smokers were allocated to receive an NHS stop smoking leaflet (usual care) or leaflet plus MiQuit (intervention).
- Women were followed-up at 4 weeks post baseline and again in late pregnancy (36 weeks gestation). Smoking status was validated biochemically in those who self-reported abstinence in late pregnancy.
- Primary outcomes were recruitment rates, follow-up (including biochemical validation) rates and combined cessation rates. Participant views on the MiQuit intervention were explored.

RESULTS

Recruitment Rates
- Target recruitment reached early
  - 407 participants in 7 months (scheduled for 12 months)

Follow-up Rates
- 72% of participants were followed-up at 4 week follow up, 64% in late pregnancy
- Biochemical validation achieved in 58% of self reported quitters
- 13% sent “STOP” texts (i.e. ended MiQuit prematurely)

Participant Attitudes to MiQuit (late pregnancy)
- 81% “definitely would” or “probably would” recommend MiQuit
- 62% found MiQuit helpful, 15% found it unhelpful
- 66% thought the number of texts was “about right” (21% thought too many & 13% thought too few)
- Type of texts found helpful (% participants):
  - development of baby (79%),
  - supportive (73%), risk information (65%),
  - advice on things to do instead of smoking (58%)

Smoking Cessation Rates

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total n (%)</th>
<th>MiQuit n (%)</th>
<th>Usual Care n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-reported 7-day point prevalence abstinence at 4 weeks post-randomisation</td>
<td>22 (5.4%)</td>
<td>15 (7.4%)</td>
<td>7 (3.4%)</td>
</tr>
<tr>
<td>Validated 7-day point prevalence abstinence at late pregnancy</td>
<td>24 (5.9%)</td>
<td>15 (7.4%)</td>
<td>9 (4.4%)</td>
</tr>
<tr>
<td>Validated abstinence from 4 weeks post-randomisation until late pregnancy</td>
<td>15 (3.7%)</td>
<td>11 (5.4%)</td>
<td>4 (2.0%)</td>
</tr>
</tbody>
</table>

Note: All 407 randomised participants were included in the analysis
(MiQuit n = 203, usual care n = 204)

QUIT attempts
- Number of quit attempts:
  - MiQuit median = 2 (IQR = 1.3), n = 124; usual care median = 1 (IQR = 0.3), n = 130; Mann-Whitney U-test P = 0.118

CONCLUSIONS
We have demonstrated that carrying out a large definitive RCT of a text message intervention for pregnant smokers would be feasible within NHS antenatal care. In this large pilot, recruitment targets were found to be both robust and achievable. Women found the intervention acceptable and relatively few stopped it prematurely, suggesting this type of self-help is likely to be a valuable approach to help pregnant women quit smoking. However, the low smoking cessation rates highlight the challenge of changing smoking behaviour in pregnancy. Although this study was not powered to detect group differences in cessation rates, results suggest a positive impact on smoking behaviour in the MiQuit arm which further warrants the undertaking of a definitive effectiveness trial. Some issues for refinement in future research were identified, including the importance of participant engagement in the study to enhance data collection.

REFERENCES